Objective: Lipodystrophy in HIV-1-infected, antiretroviral-treated-patients is often associated with opposite alterations in adipose tissue depots: lipoatrophy of subcutaneous adipose tissue (SAT) versus lipohypertrophy of visceral adipose tissue (VAT). We determined the specific molecular alterations in VAT relative to SAT in patients.
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INTRODUCTION
Lipodystrophy syndrome is among the major disturbances occurring in HIV-1-infected patients, with prevalence rates of approximately 40-50% 1 . This syndrome is characterized by a complex set of alterations in adipose tissue that mainly involve peripheral lipoatrophy-a severe loss of subcutaneous adipose tissue in the face, arms and legs-often accompanied by visceral lipohypertrophy, an enlargement in visceral adipose tissue from the abdomen and breast (in women). Less prevalent is the occurrence of lipomatosis which usually manifests as an enlargement in the dorsocervical area (i.e., "buffalo hump") 1, 2 . Although these alterations do not necessarily all occur together, the same patient may show lipoatrophy in the face and arms and enlarged adiposity in the visceral area. In addition, HIV-1 patients with lipodystrophy
show metabolic alterations reminiscent of the metabolic syndrome, particularly dyslipidemia and insulin resistance. These alterations lead to enhanced cardiovascular risk and favor the development of diabetes. Despite the fact that the trigger of the syndrome is a complex combination of HIV-1-infection and drug treatment-related events, inflammatory processes and lipotoxicity appear to be likely mechanisms for the development of the syndrome 3, 4 . The recent development of novel antiretroviral drugs with lower toxicity has led to a decrease in the frequency of overt peripheral lipoatrophy. However, visceral lipohypertrophy and associated metabolic alterations remain a common concern in treated patients 5 .
In order to understand the etiopathogenesis of lipodystrophy in HIV-1-patients, several studies have analyzed changes in gene expression appearing in adipose tissue of patients. But practically all such studies have been performed using biopsies obtained from subcutaneous fat depots, which is an adipose depot that suffers full-blown lipodystrophy [6] [7] [8] [9] . Furthermore, studies of patients with differences in HIV-1 infection status, antiretroviral treatment, and appearance of lipodystrophy suggested that some alterations in adipose tissue gene expression occur as a consequence of infection whereas other disturbances are more related to treatment or appear only in association with the establishment of full-blown lipodystrophy 8 .
Whatever its etiology, lipodystrophy syndrome can be considered a consequence of adipocyte dysfunction. However, opposite clinical changes occur in subcutaneous (lipoatrophy) versus visceral (lipohypertrophy) adipose tissues. To date, no data are available on the specific molecular alterations in visceral fat from HIV-1 patients, a limitation that surely reflects the difficulty of attaining such adipose samples.
Here we analyzed mRNA and protein expression of several markers of mitochondrial function, adipogenesis and inflammation in a unique collection of intra-abdominal visceral (omental) adipose tissue (VAT) biopsies from HIV-1-infected, HAART (Highly Active Antiretroviral Therapy)-treated patients with lipodystrophy. This specific marker gene expression profile was compared to that of abdominal subcutaneous adipose tissue (SAT) from patients, and to those of SAT and VAT from non-infected control individuals.
METHODS
All patients and controls provided informed written consent to participate in the study. The study was approved by the Ethics Committee of Hospital de la Santa Creu i 
RESULTS
Population studied.
Demographics, treatment data, anthropometric and biochemical parameters of patients and controls are shown in Table 1 . Control and patient groups were no significantly different in age, gender or BMI. The waist circumference tended to be higher in patients than in controls, but differences did not reach statistical significance. Furthermore, we analyzed how mitochondrial toxicity translates to alterations in mitochondrial proteins ( Fig 1C) . We observed that both types of adipose tissue depots from patients showed increased levels of both nuclear-encoded (ATPsynα) and mtDNA-encoded (COII) mitochondrial proteins. However, these alterations were not common to all mitochondrial proteins analyzed. For instance, complex II FeS protein levels were not significantly different among fat samples from patients compared to those from controls. For COIV protein, a significant increase was observed only in visceral fat from patients. In summary, adipose tissue from patients exhibited profound alterations in mtDNA, transcript and protein levels, in keeping with the overall mitochondrial toxicity often associated with lipodystrophy. The present data establish, however, that for most of the parameters analyzed, alterations in VAT were similar to those in SAT, and only minor differential changes appeared in the omental VAT depot of patients.
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Expression of adipogenic genes in VAT and SAT from HIV-1-infected patients.
Consistent with previous reports, the expression of the master gene for adipogenesis, PPARγ, as well as its metabolic targets involved in glucose uptake (Glut4) and fatty acid uptake (LPL) were significantly repressed in subcutaneous fat from patients ( Fig. 2A) . The same was observed for the adipokine adiponectin. In sharp contrast to the observations in subcutaneous fat, visceral fat exhibited no differences in any of the genes analyzed between patients and controls. We extended this analysis to the study of the SREBP1 protein, another master regulator of adipogenesis for which enhanced protein levels have been reported in subcutaneous fat from HIV-1-patients with lipodystrophy 6 . Effectively, SREBP1 protein levels in SAT were significantly higher in patients than in controls. In contrast, no significant difference was found for SREBP1 protein in VAT from patients (Fig. 2B) .
Analysis of the inflammation marker gene profile in VAT and SAT from HIV-1-infected patients.
We observed that SAT from patients showed high levels of the pro-inflammatory cytokine TNFα respect to healthy controls, as previously reported 6, 8 were similarly reduced in both SAT and VAT from patients. The levels of HGF, an angiogenic factor known to be released by adipose tissue under pro-inflammatory conditions 13 , were not significantly altered in any adipose tissue depot from patients relative to controls.
DISCUSSION
In the present study, we provide the first comparative characterization of the alterations in the molecular signature of VAT relative to SAT in HAART-treated, HIV-1-infected patients with lipodystrophy.
Mitochondrial toxicity is claimed to be a relevant contributor to certain features of lipodystrophy, especially peripheral lipoatrophy 14 . Collectively, the present data indicate that most of the alterations indicative of mitochondrial toxicity occur similarly in visceral and subcutaneous fat of patients, despite the opposite gross modifications in HIV-1-lipodystrophy (lipohypertrophy versus lipoatrophy in VAT and SAT, respectively).
As a general trend, all alterations commonly found in SAT from patients-mtDNA VAT. These findings suggest that mitochondrial alterations are unlikely to determine the opposite behavior of the two fat depots in response to viral-and drug-induced insults. However, the possibility that VAT is less sensitive to a given extent of mtDNA depletion than SAT cannot be excluded. It has been reported that healthy human VAT is equipped with more mitochondria and more abundant mtDNA than SAT 18 , a trend that was also observed in our study. In fact, progressive replacement of drugs with high mitochondrial toxicity (e.g. thymidine analogs) with less mitochondrial-damaging drugs in treatment regimens ameliorates signs of subcutaneous fat atrophy, but not visceral hypertrophy or induction of systemic metabolic syndrome 4, 17, 19 .
In contrast, the pattern of alterations in the expression of adipogenesis-related genes, including those encoding molecular controllers of cellular adipogenesis (PPARγ, SREBP1), as well as transporters (GLUT4) and enzymes (LPL) involved in metabolic accretion processes, was dramatically different in VAT and SAT from patients. A profound repression in the expression of these genes as well as abnormal induction of unprocessed SREBP1 protein has been reported in subcutaneous fat from patients 6, 20 , a finding confirmed in the present study. However, VAT was totally refractory to these alterations. This is consistent with the lack of atrophy of this depot and highlights the relevance of adipogenic differentiation processes in eliciting the differential alterations of fat depots in patients. . Accordingly, significant negative correlations with adipogenic markers have been reported for TNFα, but not IL-6, mRNA expression in SAT from patients 21, 25 . In any case, present analysis showed that IL-6 expression in VAT from patients was even reduced relative to controls. These observations lead to the intriguing conclusion that several features of the pro-inflammatory reaction in HIV-1 patients are moderated, and even impaired, in VAT compared with SAT. In this sense, ex-vivo studies have previously suggested a greater sensitivity of SAT than VAT to inflammation induced by protease inhibitor drugs 26 .
The preferential induction of anti-inflammatory cytokines such as IL1RN in SAT could also be a reaction to the enhanced exposure to pro-inflammatory cytokines in this adipose depot, similar to what has been reported in other conditions of proinflammatory insults in fat, such type II diabetes and obesity 27, 28 . Moreover, the
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